ZYUS Life Sciences’ (ZYU) “Buy” Rating Reiterated at Roth Capital

Roth Capital reiterated their buy rating on shares of ZYUS Life Sciences (CVE:ZYU – Free Report) in a report published on Thursday, PriceTargets.com reports. Separately, Stifel Canada reissued a speculative buy rating on shares of ZYUS Life Sciences in a research note on Friday, January 26th. Check Out Our Latest Research Report on ZYUS Life […]

Leave a Reply

Your email address will not be published.

Previous post Apollo Commercial Real Estate Finance, Inc. (NYSE:ARI) Receives $10.38 Consensus Target Price from Analysts
Next post U.S. Physical Therapy, Inc. (NYSE:USPH) Receives $119.67 Consensus PT from Brokerages